Literature DB >> 22171554

Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?

E Lader1, N Martin, G Cohen, M Meyer, P Reiter, A Dimova, D Parikh.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Warfarin, an oral anticoagulant, which has been in clinical use for over sixty years, remains a challenge for clinicians to utilize, given the multiplicity of items which can limit its efficacy. Our objective is to review the evidence and comment on whether INR control can be better than has been currently reported in various studies. COMMENT: The duration of time a patient's international normalized ratio (INR) is maintained within the therapeutic range (time in the therapeutic range, TTR) for his or her particular indication for the drug impacts the effectiveness and safety of warfarin therapy. Maintaining a therapeutic INR while on warfarin is difficult, and numerous studies employing various strategies confirm the challenge, but not the impossibility of achieving a TTR above 70%. WHAT IS NEW AND
CONCLUSION: Maintaining a therapeutic INR requires a dedicated multi-faceted approach. With diligence, skill and various therapeutic strategies, a TTR >70% can be achieved.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171554     DOI: 10.1111/j.1365-2710.2011.01324.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.

Authors:  Shin-Yu Lee; Roy Cherian; Irene Ly; Claire Horton; Alaya Levi Salley; Urmimala Sarkar
Journal:  Jt Comm J Qual Patient Saf       Date:  2017-04-20

2.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

3.  A prospective study on the use of warfarin in the United arab emirates.

Authors:  Abdulla Shehab; Asim Elnour; Abdishakur Abdulle; Abdul-Kader Souid
Journal:  Open Cardiovasc Med J       Date:  2012-06-12

4.  Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.

Authors:  Gregory Y H Lip; Xianying Pan; Shital Kamble; Hugh Kawabata; Jack Mardekian; Cristina Masseria; Amanda Bruno; Hemant Phatak
Journal:  Int J Clin Pract       Date:  2016-08-23       Impact factor: 2.503

5.  Evaluation of a Health Information Technology-Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design.

Authors:  Valy Fontil; Dhruv Kazi; Roy Cherian; Shin-Yu Lee; Urmimala Sarkar
Journal:  JMIR Res Protoc       Date:  2020-01-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.